NRSN
NeuroSense Therapeutics Ltd. [NRSN] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NRSN Stock Summary
Top 10 Correlated Stocks
NRSN
In the News
NRSN Financial details
Company Rating
-
Market Cap
21.87M
Income
-11.22M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
18
Optionable
No
Shortable
Yes
Earnings
25 May 2024
P/E
-0.92
Forward P/E
-
PEG
0.65
P/S
-
P/B
-52.53
P/C
-
P/FCF
-
Quick Ratio
1.8
Current Ratio
1.82
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.83
EPS next Y
-
EPS next Q
-
EPS this Y
-14.43%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-430.43%
-
-
-
-
SMA20
-2.65%
SMA50
1.85%
SMA100
-9.84%
Inst Own
-
Inst Trans
-
ROA
-209%
ROE
-665%
ROC
-5.2%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.4-2.33
52W High
-
52W Low
-
RSI
51.98
Rel Volume
0.34
Avg Volume
314.29K
Volume
106.78K
Perf Week
5.61%
Perf Month
0%
Perf Quarter
-12.4%
Perf Half Y
20.05%
-
-
-
-
Beta
1.56
-
-
Volatility
0.04%, 0.05%
Prev Close
-2.59%
Price
1.13
Change
-1.74%
Company Profile
- Volume Average 314.29K
- Market Capitalization 21.87M
- Employee 18
- CEO Ms. Hagit Binder
- Headquarters Herzliya,IL
- IPO Date 2021-12-09
-
Website
https://www.neurosense-tx.com 
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
